2002
Angiogenesis as a target for cancer therapy
Kaban K, Herbst RS. Angiogenesis as a target for cancer therapy. Hematology/Oncology Clinics Of North America 2002, 16: 1125-1171. PMID: 12512387, DOI: 10.1016/s0889-8588(02)00047-3.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAngiostatinsAnimalsAntibodies, MonoclonalAnticarcinogenic AgentsCell HypoxiaChildClinical Trials as TopicCollagenCyclooxygenase InhibitorsDrug DesignEndostatinsEndothelium, VascularEphrinsGrowth SubstancesHumansImmunotherapyIntegrin alphaVbeta3LigasesMatrix Metalloproteinase InhibitorsMatrix MetalloproteinasesMiceNeoplasm ProteinsNeoplasmsNeovascularization, PathologicOutcome Assessment, Health CarePeptide FragmentsPlasminogenProtease InhibitorsReceptors, Eph FamilyReceptors, Growth FactorThrombospondinsTumor Suppressor ProteinsUbiquitin-Protein LigasesVon Hippel-Lindau Tumor Suppressor ProteinAngiogenesis inhibitors in clinical development for lung cancer
Herbst RS, Hidalgo M, Pierson AS, Holden SN, Bergen M, Eckhardt SG. Angiogenesis inhibitors in clinical development for lung cancer. Seminars In Oncology 2002, 29: 66-77. PMID: 11894016, DOI: 10.1053/sonc.2002.31527.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAntineoplastic Combined Chemotherapy ProtocolsClinical Trials as TopicDisease ProgressionEndothelial Growth FactorsEndpoint DeterminationEnzyme InhibitorsHumansLung NeoplasmsLymphokinesMatrix Metalloproteinase InhibitorsMatrix MetalloproteinasesNeovascularization, PathologicTreatment OutcomeVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsConceptsAngiogenesis inhibitorsLung cancerClinical trialsClinical developmentPhase II trialLong-term administrationPlatinum-based therapyEarly clinical trialsReceptor-targeted agentsPrimary endpointAdvanced diseaseII trialMetastatic diseaseAdjunctive therapyProcess of angiogenesisCancer patientsField of angiogenesisEfficacious dosesClinical evaluationTumor regressionNovel agentsAntiangiogenic agentsTherapeutic targetDependence of tumorsTumor angiogenesis
2000
Production of Experimental Malignant Pleural Effusions Is Dependent on Invasion of the Pleura and Expression of Vascular Endothelial Growth Factor/Vascular Permeability Factor by Human Lung Cancer Cells
Yano S, Shinohara H, Herbst R, Kuniyasu H, Bucana C, Ellis L, Fidler I. Production of Experimental Malignant Pleural Effusions Is Dependent on Invasion of the Pleura and Expression of Vascular Endothelial Growth Factor/Vascular Permeability Factor by Human Lung Cancer Cells. American Journal Of Pathology 2000, 157: 1893-1903. PMID: 11106562, PMCID: PMC1885766, DOI: 10.1016/s0002-9440(10)64828-6.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAnimalsCapillary PermeabilityCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCytokinesEndothelial Growth FactorsHumansLungLung NeoplasmsLymphokinesMatrix MetalloproteinasesMiceMice, NudeNeoplasm InvasivenessNeoplasm TransplantationOligonucleotides, AntisensePleuraPleural EffusionTissue Inhibitor of MetalloproteinasesTransfectionTumor Cells, CulturedUrokinase-Type Plasminogen ActivatorVascular Endothelial Growth Factor AVascular Endothelial Growth Factors